Compare Novartis AG (NVS) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Novartis AG trades at $152.85 (market cap $295.37B), while iShares 10 20 Year Treasury Bond ETF trades at $96.79. The key difference: Novartis AG pays a 3.07% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVS | TLH | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $105.36 |
52-Week Low | $119.31 | $96.39 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
